Which GLP-1 Is Best for Me? How to Use Lab Results to Choose the Right Medication

Here is something most people don't realize when they start researching GLP-1 medications: the question is not really "which one is most popular?" — it is "which one fits my biology?"

Semaglutide and tirzepatide are both effective, clinically validated, and widely prescribed. But they are not interchangeable. They differ in their receptor targets, metabolic impact, cardiovascular data, and FDA indications — and those differences matter significantly depending on what your lab work shows. Choosing based on social media trends, cost alone, or what worked for a friend means skipping the one clinical tool that can actually tell you which medication aligns with your metabolic profile: your blood work.

This guide is designed for anyone who has labs in hand — or who is about to get them — and wants to understand what those results actually mean for GLP-1 selection. We will walk through the specific markers that matter, how to interpret them in the context of the available GLP-1 medications, and what a genuinely informed conversation with your prescriber should look like.

Why Your Lab Results Are the Starting Point — Not an Afterthought

GLP-1 receptor agonists work by mimicking a natural gut hormone that regulates insulin secretion, appetite, and gastric emptying. But the clinical population using them spans a wide range — from individuals with established type 2 diabetes and cardiovascular disease to otherwise healthy adults with obesity and no comorbidities. That range is precisely why labs matter.

A baseline metabolic panel serves two functions simultaneously: it screens for safety (contraindications, organ function limits, thyroid concerns) and it maps the terrain of your metabolic dysfunction, which guides drug selection. Your A1C level, for example, does not just tell you whether you have diabetes — it tells your clinician how much glycemic control you need and which GLP-1 agent has demonstrated superiority at that level. Your kidney function does not just clear you for treatment — it may actively point toward a medication with documented renal-protective data.

Understanding your own labs does not replace your clinician's judgment. It sharpens the conversation.

The five lab panels that matter most for GLP-1 selection: HbA1c and fasting glucose, lipid panel, kidney function (eGFR/creatinine), liver enzymes (ALT/AST), and thyroid function (TSH/calcitonin). Each is covered in detail below.

If you are starting GLP-1 therapy without blood work, you are making a treatment decision with incomplete clinical information. That is a problem worth taking seriously.

The Five Core Lab Panels — What to Test and What They Tell You

HbA1c and Fasting Blood Glucose

HbA1c — also called A1C or glycated hemoglobin — measures your average blood sugar over the past two to three months. It is the single most informative marker for GLP-1 selection because it reflects the severity of glucose dysregulation and directly informs FDA-indicated use.

This last point deserves emphasis. In the SURPASS-2 trial — a direct head-to-head comparison of tirzepatide versus semaglutide in type 2 diabetes — tirzepatide at its maximum dose reduced HbA1c by 2.46 percentage points compared to 1.86 for semaglutide, a statistically significant difference (Frias et al., NEJM, 2021). For patients with an A1C above 8.5%, that gap is clinically meaningful.

Also note that FDA labeling distinguishes between weight management and diabetes indications. Wegovy and Zepbound carry obesity labels; Ozempic and Mounjaro carry type 2 diabetes labels, though both are widely used off-label for weight management. Your A1C result is the clearest guide to which label — and therefore which insurance pathway — applies to you. Learn more about prediabetes and how it influences treatment decisions on Meto.

Lipid Panel (Total Cholesterol, LDL, HDL, Triglycerides)

GLP-1 receptor agonists have established cardioprotective properties, but the strength and source of that evidence varies significantly between agents. Your lipid panel helps identify where that evidence is most relevant to you.

Semaglutide has the deepest cardiovascular outcomes data. The SUSTAIN-6 trial demonstrated a 26% reduction in major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established CV disease (Marso et al., NEJM, 2016). More recently, the SELECT trial extended that finding to individuals without diabetes but with established cardiovascular disease and obesity — a population that had not previously been covered by outcomes data (Lincoff et al., NEJM, 2023). If your lipid panel shows elevated LDL and your history includes atherosclerotic cardiovascular disease, that evidence profile carries real weight.

Triglycerides deserve separate attention. GLP-1 agents as a class produce significant triglyceride reduction — and if your panel shows fasting triglycerides above 200 mg/dL, this becomes an additional therapeutic target, not just a background metric.

Patients managing dyslipidemia alongside obesity or diabetes have a distinct set of considerations when selecting a GLP-1 agent.

Kidney Function — eGFR and Creatinine

Estimated glomerular filtration rate (eGFR) measures how efficiently your kidneys are filtering blood. It matters for GLP-1 selection for two reasons: safety and therapeutic advantage.

From a safety standpoint, severe renal impairment can affect drug clearance and tolerability. Most GLP-1 agents are cleared via peptide degradation rather than renal excretion, which means they are generally well-tolerated across a wide eGFR range — but clinical guidelines recommend caution in severe CKD, and monitoring frequency increases.

More importantly, semaglutide now has direct renal outcomes data. The FLOW trial — a dedicated cardiovascular-renal outcomes study — demonstrated that semaglutide reduced the progression of kidney disease and the risk of kidney failure in patients with type 2 diabetes and CKD, reducing the primary composite renal endpoint by 24% (Perkovic et al., NEJM, 2024). If your eGFR shows moderate CKD (stages 2–3, roughly eGFR 30–59), this data is directly relevant to which agent your clinician is likely to prioritize.

Liver Enzymes — ALT and AST

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are the primary markers of hepatocyte stress. Elevated levels — typically defined as more than twice the upper limit of normal — can indicate metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD/NASH), which has significant overlap with the same population using GLP-1 medications.

Both semaglutide and tirzepatide have shown reductions in liver fat in metabolic liver disease, but tirzepatide's dual GLP-1/GIP mechanism appears to have a particularly pronounced effect on hepatic steatosis. Early trial data and clinical subgroup analyses from SURMOUNT-1 support this observation, and dedicated liver disease trials are ongoing. For patients with elevated ALT/AST in the context of suspected fatty liver disease, tirzepatide's emerging liver data may shift the conversation.

That said, markedly elevated transaminases (more than three times the upper limit of normal) warrant a full hepatic workup before initiating any GLP-1 agent, and some cases may require hepatology input.

Thyroid Function — TSH and Calcitonin

This is one of the most important safety checks — and one of the most frequently misunderstood. All GLP-1 receptor agonists carry a black box warning for medullary thyroid carcinoma (MTC) based on animal studies showing thyroid C-cell tumors at supratherapeutic doses. This is a contraindication — not a theoretical concern — for anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN2).

Serum calcitonin is the relevant biomarker here. A significantly elevated calcitonin level in a patient with no prior history should prompt a thyroid workup before initiating therapy. The FDA does not require routine calcitonin monitoring, but many metabolically experienced clinicians include it as part of a comprehensive baseline panel — particularly in patients with thyroid nodules or a family history of thyroid disease.

TSH screening is also warranted because untreated hypothyroidism can mask or mimic the metabolic dysfunction that GLP-1s are being used to address. Optimizing thyroid status before initiating a GLP-1 provides cleaner data on medication response and may affect how aggressively the drug needs to be dosed.

Summary: Lab Markers and Their GLP-1 Implications at a Glance

Step-by-Step — How to Use Your Labs to Guide Your GLP-1 Decision

Step 1: Gather a complete baseline panel before your appointment

At minimum, request: HbA1c, fasting glucose, fasting insulin, comprehensive metabolic panel (CMP), lipid panel, TSH, and — if indicated — calcitonin. If your history suggests liver disease, request ALT, AST, and GGT. For a detailed breakdown of how to order these without an in-person visit, see Meto's guide on how to get GLP-1 lab work without a doctor visit.

Not sure what a metabolic panel actually measures or how to read one? Meto's metabolic panel results explainer is a useful primer.

Step 2: Clarify your primary treatment goal

This is not a trick question, but the answer matters. If your primary driver is blood sugar control with weight loss as secondary, your prescriber will lean toward diabetes-labeled agents (Ozempic or Mounjaro) and your A1C will anchor the decision. If your primary driver is weight management without diagnosed diabetes, your eligibility and insurance pathway shift toward obesity-labeled agents (Wegovy or Zepbound). Your HbA1c and BMI combination together determine which FDA-approved framework applies to you.

Step 3: Map your metabolic risk profile using the lab data

Ask yourself — or your clinician — which of the following applies:

• Elevated cardiovascular risk or established ASCVD? → Prioritize semaglutide's SELECT and SUSTAIN-6 data
• High A1C (above 8.5%) with significant weight to lose? → Tirzepatide's dual mechanism shows superior results in both dimensions
• Moderate CKD (eGFR 30–59) with type 2 diabetes? → Semaglutide's FLOW trial data is directly applicable
• Elevated liver enzymes and suspected MASLD? → Tirzepatide's GIP + GLP-1 mechanism shows emerging hepatic benefit
• Personal or family history of MTC or MEN2? → All GLP-1 agents are contraindicated; discuss alternatives including metformin

Step 4: Screen your results for contraindications

Beyond the thyroid, review for a history of pancreatitis (though causality with GLP-1s remains debated, it warrants discussion), symptomatic gallbladder disease, and any personal history of MEN2. These are not always captured in a standard metabolic panel but should be part of your medical history disclosure.

Step 5: Come to your appointment with targeted questions

Do not walk in and say "which one is better?" Walk in with: "Given my A1C of X, eGFR of Y, and these triglyceride levels, what is your rationale for the agent you're recommending — and what does the outcomes data say for someone with my profile?" That question signals clinical engagement and gets you a much more specific answer.

Semaglutide vs. Tirzepatide — What the Labs Actually Tell You

This is the comparison most people are looking for — and the answer is more nuanced than "tirzepatide is stronger."

The core mechanistic difference is this: semaglutide is a selective GLP-1 receptor agonist. Tirzepatide adds GIP (glucose-dependent insulinotropic polypeptide) receptor agonism — making it a dual incretin agent. That additional pathway amplifies insulin sensitivity, enhances fat cell metabolism, and appears to have additive effects on body weight and glycemic control. That is the pharmacological reason why SURMOUNT-1 showed tirzepatide achieving up to 22.5% mean body weight reduction at the highest dose — a figure that significantly exceeds what was seen in semaglutide's STEP trials (Jastreboff et al., NEJM, 2022).

But "stronger" does not automatically mean "better for you."

When the labs point toward semaglutide:

• Established atherosclerotic cardiovascular disease (ASCVD) — the SELECT trial data remains semaglutide's most compelling differentiator
• Moderate-to-severe CKD with type 2 diabetes — FLOW trial evidence is specific to semaglutide
• A patient who has previously responded to a GLP-1 class drug and is tolerating the mechanism well
• Oral administration preference — Rybelsus (oral semaglutide) is the only approved oral GLP-1 option for patients who cannot tolerate or prefer to avoid injections

When the labs point toward tirzepatide:

• HbA1c above 8.5% with a BMI above 35 — tirzepatide's superior glycemic and weight outcomes data is most relevant at these levels
• Elevated fasting insulin or HOMA-IR suggesting significant insulin resistance — the GIP receptor pathway specifically targets insulin sensitivity in a complementary mechanism
• Elevated ALT/AST in the context of MASLD — tirzepatide's effect on hepatic steatosis is more pronounced in early data
• A patient who has not responded adequately to a GLP-1-only agent after an appropriate trial period

Side-by-Side Lab Profile Comparison

Monitoring Labs After Starting a GLP-1

The lab conversation does not end at initiation. Ongoing monitoring tells you whether the medication is working at a metabolic level — and catches adverse signals before they become clinical problems. For a detailed breakdown of which biomarkers to track and at what frequency, Meto's guide to 10 biomarkers every GLP-1 patient should monitor covers this comprehensively.

If HbA1c fails to improve meaningfully after 3–6 months at an adequate dose, that is a data point — and a reason to revisit the choice of agent, dose, or adherence rather than simply continuing without adjustment. Also see Meto's clinical guide to 5 dangerous GLP-1 side effects that labs can catch early, particularly regarding liver stress, pancreatitis signals, and renal changes.

When Lab Results Alone Are Not the Whole Answer

A metabolically sophisticated decision incorporates labs as one input — not the only input. Several practical factors that are not captured in blood work also shape which GLP-1 is the right fit:

Insurance and formulary access. Despite comparable clinical profiles in some patients, payer coverage for tirzepatide versus semaglutide can differ significantly depending on your insurer, your diagnosis code, and whether you have an obesity or diabetes indication. The best medication clinically is the one you can actually access and afford consistently.

Injection vs. oral preference. For patients with needle aversion or practical barriers to injection, Rybelsus (oral semaglutide) offers a meaningful alternative — though absorption is more variable and it requires strict fasting protocols. Understanding that this option exists is part of the selection decision.

GI history and tolerability. Nausea, vomiting, and delayed gastric emptying are class-wide effects, but the severity and timing differ between agents. A patient with a history of esophageal dysmotility or severe GERD may need slower dose titration and careful agent selection — a nuance that labs will not capture.

Polypharmacy. Patients on insulin, sulfonylureas, or SGLT-2 inhibitors need adjustment conversations when adding a GLP-1 — the interaction is not dangerous, but the hypoglycemia risk changes. This is a clinical conversation your prescriber needs to lead.

Provider experience. As GLP-1 telehealth prescribing has expanded rapidly, the quality of clinical oversight varies considerably. A prescriber experienced with metabolic medicine will interpret your labs in context; one simply filling a prescription form may not.

Meto's Clinical Perspective — Why Labs Come First

At Meto, we have built our approach to weight loss, prediabetes, and metabolic syndrome care on a single foundational belief: treatment decisions should follow data, not assumptions.

In our clinical experience, the patients who benefit most from GLP-1 therapy — and who sustain those benefits over time — are the ones who enter treatment understanding their metabolic profile. They know their A1C. They know whether their kidneys need specific monitoring. They have discussed their thyroid history with their provider. They are not surprised six weeks in by side effects that could have been anticipated from their baseline labs.

The opposite scenario — initiating a GLP-1 without baseline blood work, on the recommendation of a social media post or a five-minute telehealth consult — is not just clinically suboptimal. It removes the feedback loop that tells you whether the medication is working at a metabolic level, not just on the scale.

That is why Meto's Prescription Weight Loss Program includes clinician-reviewed labs as a core component, not an optional add-on. And it is why we offer a dedicated Comprehensive Metabolic Panel — including HbA1c, fasting glucose and insulin, lipid panel, CMP, liver markers, and inflammation markers — specifically designed to give our patients and their clinicians the information they need to make a well-grounded GLP-1 decision.

If you have been considering a GLP-1 medication and have not yet ordered your labs, or if you have results in hand and want a clinician who can interpret them in the context of your full metabolic picture, this is where we start.

✦ Ready to Make a Lab-Informed GLP-1 Decision?

Meto's Comprehensive Metabolic Panel ($199) includes every biomarker discussed in this article — HbA1c, fasting glucose and insulin, lipid panel, comprehensive metabolic panel, liver markers, and inflammation markers — with a personalized metabolic report and clinician review.

Order Your Lab Panel →

Already have results? Start your clinical intake and get matched with a Meto provider →

Conclusion

The right GLP-1 medication is not a universal answer — it is a data-driven match between your metabolic profile and a specific drug's mechanism, safety data, and outcomes evidence. Your HbA1c tells you how much glycemic work needs to be done. Your eGFR tells you whether renal protection should factor into the choice. Your cardiovascular history and lipid panel tell you whose outcomes data is most relevant. Your thyroid labs screen for the one contraindication that cannot be overlooked.

None of that is complicated once you know what to look for. The five lab panels in this guide, the step-by-step framework, and the semaglutide-versus-tirzepatide comparison give you the tools to walk into that conversation — with your prescriber, with a Meto clinician, or with your own research — prepared to ask better questions and get more specific answers.

Your labs are a map. This is how you read it.

Related reading from Meto:

• Labs Before Semaglutide: Complete GLP-1 Blood Work Guide
• GLP-1 Lab Testing Explained: 15 Common Questions Answered
• 10 Biomarkers Every GLP-1 Patient Should Track
• 5 Dangerous GLP-1 Side Effects Labs Can Catch Early
• Is GLP-1 Without Blood Work Safe?
• At-Home Lab Testing for Weight Loss: Best Providers Compared

Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice. Always consult a licensed clinician before initiating, switching, or stopping any GLP-1 medication.